Hunninghake D B, Stein E A, Dujovne C A, Harris W S, Feldman E B, Miller V T, Tobert J A, Laskarzewski P M, Quiter E, Held J
Heart Disease Prevention Clinic, Minneapolis, MN 55455.
N Engl J Med. 1993 Apr 29;328(17):1213-9. doi: 10.1056/NEJM199304293281701.
A diet low in saturated fat and cholesterol is the standard initial treatment for hypercholesterolemia. However, little quantitative information is available about the efficacy of dietary therapy in clinical practice or about the combined effects of diet and drug therapy.
One hundred eleven outpatients with moderate hypercholesterolemia were treated at five lipid clinics with the National Cholesterol Education Program Step 2 diet (which is low in fat and cholesterol) and lovastatin (20 mg once daily), both alone and together. A diet high in fat and cholesterol and a placebo identical in appearance to the lovastatin were used as the respective controls. Each of the 97 patients completing the study (58 men and 39 women) underwent four consecutive nine-week periods of treatment according to a randomized, balanced design: a high-fat diet-placebo period, a low-fat diet-placebo period, a high-fat diet-lovastatin period, and a low-fat diet-lovastatin period.
The level of low-density lipoprotein (LDL) cholesterol was a mean of 5 percent (95 percent confidence interval, 3 to 7 percent) lower during the low-fat diet than during the high-fat diet (P < 0.001). With lovastatin therapy as compared with placebo, the reduction was 27 percent. Together, the low-fat diet and lovastatin led to a mean reduction of 32 percent in the level of LDL cholesterol. The level of high-density lipoprotein (HDL) cholesterol fell by 6 percent (95 percent confidence interval, 4 to 8 percent) during the low-fat diet (P < 0.001) and rose by 4 percent during treatment with lovastatin (P < 0.001). The ratio of LDL to HDL cholesterol and the level of total triglycerides were reduced by lovastatin (P < 0.001), but not by the low-fat diet.
The effects of the low-fat-low-cholesterol diet and lovastatin on lipoprotein levels were independent and additive. However, the reduction in LDL cholesterol produced by the diet was small, and its benefit was possibly offset by the accompanying reduction in the level of HDL cholesterol.
低饱和脂肪和胆固醇饮食是高胆固醇血症的标准初始治疗方法。然而,关于饮食疗法在临床实践中的疗效以及饮食与药物疗法联合作用的定量信息很少。
111例中度高胆固醇血症门诊患者在5家血脂诊所接受治疗,采用国家胆固醇教育计划第二步饮食(低脂、低胆固醇)和洛伐他汀(每日一次,20毫克),分别单独使用和联合使用。高脂肪、高胆固醇饮食和外观与洛伐他汀相同的安慰剂分别作为对照。完成研究的97例患者(58例男性和39例女性)中的每例均按照随机、平衡设计接受连续四个为期九周的治疗阶段:高脂肪饮食-安慰剂阶段、低脂肪饮食-安慰剂阶段、高脂肪饮食-洛伐他汀阶段和低脂肪饮食-洛伐他汀阶段。
与高脂肪饮食期间相比,低脂肪饮食期间低密度脂蛋白(LDL)胆固醇水平平均降低5%(95%置信区间为3%至7%)(P<0.001)。与安慰剂相比,洛伐他汀治疗使LDL胆固醇降低27%。低脂肪饮食和洛伐他汀共同作用使LDL胆固醇水平平均降低32%。高密度脂蛋白(HDL)胆固醇水平在低脂肪饮食期间下降6%(95%置信区间为4%至8%)(P<0.001),在洛伐他汀治疗期间上升4%(P<0.001)。LDL与HDL胆固醇的比值以及总甘油三酯水平因洛伐他汀而降低(P<0.001),但不受低脂肪饮食影响。
低脂肪、低胆固醇饮食和洛伐他汀对脂蛋白水平的影响是独立且相加的。然而,饮食导致的LDL胆固醇降低幅度较小,其益处可能被伴随的HDL胆固醇水平降低所抵消。